134 related articles for article (PubMed ID: 31628917)
1. Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations.
Ikonomov OC; Sbrissa D; Shisheva A
Toxicol Appl Pharmacol; 2019 Nov; 383():114771. PubMed ID: 31628917
[TBL] [Abstract][Full Text] [Related]
2. PIKfyve inhibitor cytotoxicity requires AKT suppression and excessive cytoplasmic vacuolation.
Ikonomov OC; Altankov G; Sbrissa D; Shisheva A
Toxicol Appl Pharmacol; 2018 Oct; 356():151-158. PubMed ID: 30098992
[TBL] [Abstract][Full Text] [Related]
3. Functional dissociation between PIKfyve-synthesized PtdIns5P and PtdIns(3,5)P2 by means of the PIKfyve inhibitor YM201636.
Sbrissa D; Ikonomov OC; Filios C; Delvecchio K; Shisheva A
Am J Physiol Cell Physiol; 2012 Aug; 303(4):C436-46. PubMed ID: 22621786
[TBL] [Abstract][Full Text] [Related]
4. Apilimod, a candidate anticancer therapeutic, arrests not only PtdIns(3,5)P2 but also PtdIns5P synthesis by PIKfyve and induces bafilomycin A1-reversible aberrant endomembrane dilation.
Sbrissa D; Naisan G; Ikonomov OC; Shisheva A
PLoS One; 2018; 13(9):e0204532. PubMed ID: 30240452
[TBL] [Abstract][Full Text] [Related]
5. Active vacuolar H+ ATPase and functional cycle of Rab5 are required for the vacuolation defect triggered by PtdIns(3,5)P2 loss under PIKfyve or Vps34 deficiency.
Compton LM; Ikonomov OC; Sbrissa D; Garg P; Shisheva A
Am J Physiol Cell Physiol; 2016 Sep; 311(3):C366-77. PubMed ID: 27335171
[TBL] [Abstract][Full Text] [Related]
6. Development of Three Orthogonal Assays Suitable for the Identification and Qualification of PIKfyve Inhibitors.
Fogarty K; Kashem M; Bauer A; Bernardino A; Brennan D; Cook B; Farrow N; Molinaro T; Nelson R
Assay Drug Dev Technol; 2017 Jul; 15(5):210-219. PubMed ID: 28723271
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of PIKfyve using YM201636 suppresses the growth of liver cancer via the induction of autophagy.
Hou JZ; Xi ZQ; Niu J; Li W; Wang X; Liang C; Sun H; Fang D; Xie SQ
Oncol Rep; 2019 Mar; 41(3):1971-1979. PubMed ID: 30569119
[TBL] [Abstract][Full Text] [Related]
8. Class III PI 3-kinase is the main source of PtdIns3P substrate and membrane recruitment signal for PIKfyve constitutive function in podocyte endomembrane homeostasis.
Ikonomov OC; Sbrissa D; Venkatareddy M; Tisdale E; Garg P; Shisheva A
Biochim Biophys Acta; 2015 May; 1853(5):1240-50. PubMed ID: 25619930
[TBL] [Abstract][Full Text] [Related]
9. The Lipid Kinase PIKfyve Coordinates the Neutrophil Immune Response through the Activation of the Rac GTPase.
Dayam RM; Sun CX; Choy CH; Mancuso G; Glogauer M; Botelho RJ
J Immunol; 2017 Sep; 199(6):2096-2105. PubMed ID: 28779020
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of PIKfyve by YM-201636 dysregulates autophagy and leads to apoptosis-independent neuronal cell death.
Martin S; Harper CB; May LM; Coulson EJ; Meunier FA; Osborne SL
PLoS One; 2013; 8(3):e60152. PubMed ID: 23544129
[TBL] [Abstract][Full Text] [Related]
11. Essential roles of PIKfyve and PTEN on phagosomal phosphatidylinositol 3-phosphate dynamics.
Hazeki K; Nigorikawa K; Takaba Y; Segawa T; Nukuda A; Masuda A; Ishikawa Y; Kubota K; Takasuga S; Hazeki O
FEBS Lett; 2012 Nov; 586(22):4010-5. PubMed ID: 23068606
[TBL] [Abstract][Full Text] [Related]
12. A selective PIKfyve inhibitor blocks PtdIns(3,5)P(2) production and disrupts endomembrane transport and retroviral budding.
Jefferies HB; Cooke FT; Jat P; Boucheron C; Koizumi T; Hayakawa M; Kaizawa H; Ohishi T; Workman P; Waterfield MD; Parker PJ
EMBO Rep; 2008 Feb; 9(2):164-70. PubMed ID: 18188180
[TBL] [Abstract][Full Text] [Related]
13. The PIKfyve-ArPIKfyve-Sac3 triad in human breast cancer: Functional link between elevated Sac3 phosphatase and enhanced proliferation of triple negative cell lines.
Ikonomov OC; Filios C; Sbrissa D; Chen X; Shisheva A
Biochem Biophys Res Commun; 2013 Oct; 440(2):342-7. PubMed ID: 24070605
[TBL] [Abstract][Full Text] [Related]
14. PIKfyve-Dependent Phosphoinositide Dynamics in Megakaryocyte/Platelet Granule Integrity and Platelet Functions.
Caux M; Mansour R; Xuereb JM; Chicanne G; Viaud J; Vauclard A; Boal F; Payrastre B; Tronchère H; Severin S
Arterioscler Thromb Vasc Biol; 2022 Aug; 42(8):987-1004. PubMed ID: 35708031
[TBL] [Abstract][Full Text] [Related]
15. PIKfyve: Partners, significance, debates and paradoxes.
Shisheva A
Cell Biol Int; 2008 Jun; 32(6):591-604. PubMed ID: 18304842
[TBL] [Abstract][Full Text] [Related]
16. PIKfyve inhibition interferes with phagosome and endosome maturation in macrophages.
Kim GH; Dayam RM; Prashar A; Terebiznik M; Botelho RJ
Traffic; 2014 Oct; 15(10):1143-63. PubMed ID: 25041080
[TBL] [Abstract][Full Text] [Related]
17. PIKfyve, MTMR3 and their product PtdIns5P regulate cancer cell migration and invasion through activation of Rac1.
Oppelt A; Haugsten EM; Zech T; Danielsen HE; Sveen A; Lobert VH; Skotheim RI; Wesche J
Biochem J; 2014 Aug; 461(3):383-90. PubMed ID: 24840251
[TBL] [Abstract][Full Text] [Related]
18. PIKfyve accelerates phagosome acidification through activation of TRPML1 while arrests aberrant vacuolation independent of the Ca2+ channel.
Isobe Y; Nigorikawa K; Tsurumi G; Takemasu S; Takasuga S; Kofuji S; Hazeki K
J Biochem; 2019 Jan; 165(1):75-84. PubMed ID: 30295876
[TBL] [Abstract][Full Text] [Related]
19. Unexpected inhibition of the lipid kinase PIKfyve reveals an epistatic role for p38 MAPKs in endolysosomal fission and volume control.
Wible DJ; Parikh Z; Cho EJ; Chen MD; Jeter CR; Mukhopadhyay S; Dalby KN; Varadarajan S; Bratton SB
Cell Death Dis; 2024 Jan; 15(1):80. PubMed ID: 38253602
[TBL] [Abstract][Full Text] [Related]
20. Plentiful PtdIns5P from scanty PtdIns(3,5)P2 or from ample PtdIns? PIKfyve-dependent models: Evidence and speculation (response to: DOI 10.1002/bies.201300012).
Shisheva A; Sbrissa D; Ikonomov O
Bioessays; 2015 Mar; 37(3):267-77. PubMed ID: 25404370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
